Contributing to a world free from vaccine-preventable and neglected tropical diseases
To improve access to vaccination and disease control programmes by supporting public and non-profit clients in developing, implementing and evaluating evidence-based policies, strategies, products and tools
Our Services
A world where everyone enjoys a life free from vaccine-preventable and neglected tropical diseases
Explore Our WorkImmunisation prevents an estimated 3.5 to 5 million deaths every year. Coverage has plateaued: more than 13 million infants still receive no vaccine at all, and millions more start the schedule without completing it.
Using our public health experience and implementation and academic backgrounds, we have assembled an optimal team to ensure that all immunisation programmes have the best chance of success.
Service Offerings
Access
Enable improved access to vaccines and diagnostic products.
Programme Implementation
Support the effective implementation of immunisation and diagnostic programmes.
Policy and Strategy
Strengthen disease control policies and strategies by advising on their development
Evaluation
Conduct evaluations to support the productive and beneficial functioning of organisations and activities in the vaccine ecosystem
Team Members in
4 cities
Clients in
16 cities
Research Conducted in
27 countries
Our Clients
Disclaimer: The organisations shown here indicate supplier-client relationships. MMGH has no formal relationship with these organisations nor does this listing indicate any form of endorsement of MMGH’s work beyond the award of past or present contract(s).
Latest Publications
2026 - Report
Advancing heat-stable vaccines: Vaccine Innovation Prioritisation Strategy (VIPS) consultation on...
The Vaccine Innovation Prioritisation Strategy (VIPS) identified heat stability and controlled temperature chain in 2020 as a priority innovation for partner support. This report sets out what countries themselves want from it. Drawing on interviews and...
Publication
Gavi, the Vaccine Alliance
View PublicationGavi, the Vaccine Alliance
2026 - Journal Article
A prioritised research agenda to inform the introduction and use...
Lassa fever is a viral haemorrhagic disease endemic in West Africa, and several vaccine candidates are currently in development. To help ensure that future vaccine decisions are timely, evidence-informed, and aligned with country needs, we convened...
Publication
Building the evidence base for future Lassa fever vaccine decisions
View PublicationBuilding the evidence base for future Lassa fever vaccine decisions
2026 - Journal Article
Priority implementation research for measles-rubella microarray patches identified using the...
Measles-rubella microarray patches are an innovative vaccine delivery technology in development that could help improve immunisation coverage and equity in low- and middle-income countries. To support future introduction, we used the Child Health and Nutrition Research...
Publication
Preparing for the introduction of measles-rubella microarray patches
View PublicationPreparing for the introduction of measles-rubella microarray patches
2026 - Journal Article
Evaluating the broader impact of improved influenza vaccines: A full...
Seasonal influenza remains a significant global public health challenge, causing substantial morbidity and mortality each year and there remains a need for more effective and durable influenza vaccines. To direct and accelerate research efforts, a full...
Publication
View Publication
2026 - Journal Article
Health Worker Influenza Vaccination Programs: A Key to Pandemic Preparedness...
The COVID-19 pandemic created an urgent need to rapidly vaccinate health workers and the broader population. This analysis examined whether low- and middle-income countries with established influenza vaccination programs for health workers were better positioned to...
Publication
View Publication
2024 - Journal Article
WHO Global Market Study on respiratory syncytial virus immunization products...
MI4A produces antigen-specific market studies, analyzing global demand and supply dynamics for products targeting a specific antigen. The Global Market Study on RSV Immunization Products aims to identify early potential obstacles to equitable access to RSV...
Publication
WHO
View PublicationWHO
Contact the MMGH Team
To find out how we can assist with your upcoming projects, please fill in this form and someone from our team will contact you shortly.
If you would like to join our team, please see our job openings here or send a speculative application by emailing your CV and a brief cover letter to info@mmglobalhealth.org
If you would like to join our team, please see our job openings here or send a speculative application by emailing your CV and a brief cover letter to info@mmglobalhealth.org
Headquarters:
MMGH Consulting GmbH
Kuerbergstrasse 1
8049 Zurich, Switzerland
+41 44 553 04 53
Branch:
MMGH Consulting GmbH
Chemin Maurice-Ravel 11C
1290 Versoix, Switzerland
+41 22 596 78 60